Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417612 · ClinicalTrials.gov registry record · Phase 3
Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
A Phase 3 study of Hyperparathyroidism and Hypophosphatemia, Familial, sponsored by Yale University.
- Completed
- Registry status
- Phase 3
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00417612 is a Phase 3 study of Hyperparathyroidism and Hypophosphatemia, Familial that has completed, run by Yale University. The registered enrollment target is 33 participants, below the 129-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00417612, a Phase 3 study of Hyperparathyroidism and Hypophosphatemia, Familial, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of paricalcitol, a form of synthetic vitamin D, in lowering parathyroid hormone (PTH) levels and reducing disease symptoms in children and adults with X-linked hypophosphatemic (XLH) rickets.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Paricalcitol
Study Locations (1)
Connecticut
- Yale University School of Medicine - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00417612
The ClinicalTrials.gov registry entry for NCT00417612 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 7 other Hyperparathyroidism trials with a reported enrollment target (74% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hyperparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00417612 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00417612 about?
NCT00417612 is a clinical study titled "Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets". The purpose of this study is to determine the effectiveness of paricalcitol, a form of synthetic vitamin D, in lowering parathyroid hormone (PTH) levels and reducing disease symptoms in children and adults with X-linked hypophosphatemic (XLH) rickets.
What is the current status of trial NCT00417612?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 33 participants. The study started on 2007-01. Estimated completion is 2012-08.
What conditions does trial NCT00417612 study?
This clinical trial studies the following conditions: Hyperparathyroidism, Hypophosphatemia, Familial.
What interventions are being tested in trial NCT00417612?
The interventions under investigation include: Placebo (OTHER), Paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00417612?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00417612 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
COMPLETED · Phase 3
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Parathyroidectomy and Mobility Study
RECRUITING
-
STP.168 Clinical Study Protocol Parakeet
ACTIVE NOT RECRUITING · NA
-
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
ACTIVE NOT RECRUITING · NA
-
One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.